Recent

% | $
Quotes you view appear here for quick access.

Avanir Pharmaceuticals, Inc. Message Board

  • andrewtsai89 andrewtsai89 Feb 14, 2013 7:08 PM Flag

    CANNACORD FEB 2013 ANALYST REPORT THUMBS ME UP

     

    THUMBS UP OR NO MORE REPORTS

    "Reiterate BUY, $6 target on continued Nuedexta growth, robust sales estimates. Nuedexta is AVNR’s drug for pseudobulbar
    affect, emotional lability seen in stroke, traumatic brain injury, Alzheimer’s and other neurodegenerative disorders. Launch
    has been steady, and we see new positive trends. Our peak annual sales estimates are $350M US, $300M EU. Our $6 target is
    based on a sum-of- the-parts analysis."

    "AVP-786 (deuterated dextromethorphan) formulation shows similar PK, safety to Nuedexta with substantially less
    quinidine"
    "AVNR will cut size of PRIME study in half as the company shifts development focus to AVP-786"

    This topic is deleted.
 
AVNR
16.960.00(0.00%)Jan 12 3:59 PMEST